CBX3 and ovarian cancer: Based on the above expression and prognosis results of CBX family members, we found that only CBX3 was overexpressed in ovarian cancer tissues and closely related to the poor prognosis (OS and PFS) of patients with OV at the same time, indicating that CBX3 is the most likely potential diagnostic indicator and new therapeutic target for patients with ovarian cancer.